From the Petrobras wipeout to the actual plunge, Brazil runs the Cellof Deep


Billionaire Ray Dalio bets on 3 “Strong Buy” stocks

When billionaire financier Ray Dalio makes a move, Wall Street pays attention. Dalio, who started working on the floor of the New York Stock Exchange trading commodity futures, founded Bridgewater Associates, the world’s largest hedge fund, in 1975. The company, which manages about 140 140 billion in global investments, has its own net worth. Billion 17 billion, he has achieved great position on Wall Street. Summarizing its success, Dalio has three pieces of advice for investors. First, diversity. Having a large number of stocks in a portfolio from multiple sectors is a surefire way to invest well. Second, don’t think that growing markets will grow forever. This is an old-fashioned view that past performance does not guarantee future returns. Dalio tells you that the guarantees of all the strong returns of the past are really high prices. And finally, Dalio tells investors, “Do the opposite of what your instincts are.” Or put another way, don’t follow the crowd, as such thinking often leads to suboptimal results. Turning to Dalio for investment incentives, we used Tiparenx’s database to find out if the three stocks currently added to the fund represent billionaires. According to the platform, the analyst community believes that as they do, all have received “Strong By” consensus ratings. Linde P.L.C. (LNN) The first new location belongs to Linde, the world’s largest industrial gas producer, whether in terms of revenue or market share. Linde produces a wide variety of gases for industrial use, and is a strong supplier of argon, nitrogen, oxygen, and hydrogen to the soft drink industry, with specific gases such as carbon dioxide. The company also manufactures gas storage and transfer equipment, welding equipment and refrigerants. In short, Linde sculpts Dalio’s ‘diversified’ attitude. Linde’s industry leadership and essential products helped the company recover from the Corona crisis. The company’s revenue slipped to 1H20, but rose in the second half, reaching pre-core levels in Q3 and surpassing that level in Q4. In a sign of confidence, the company maintained a dividend of 96 cents per share during its “Corona year” – and in its most recent Q1 announcement, Linde increased its payout per share to 1.06 dir. This gives an annualization of 4.24 and yields 1.7%. The key issue here is not modest yields, but confidence in the safety of the company’s position, allowing it to keep a steady dividend while many partners are cutting dividends in profits. Not surprisingly, investors like Dalio would be interested in a company like Linde. The billionaire’s fund has jumped to 20,149 stocks during the fourth quarter, at current prices of 5.05 million. Evaluating Linde for BMOs, analyst John Mankality expresses confidence in Linde’s current performance. “Lynn continues to implement its growth strategy, especially without the need for further macro reform, to grow solid double-digit earnings. In our view, the management’s 11-13% guideline for 2021 has been to stay afloat through its upcoming projects, pricing Will continue, gain in efficiency, and with its strong balance sheet and cash flow solid bibxx forward, solid FCF position M&A, D-caps etc. provide them plenty of dry powder. Ready. Also a group in a cyclical market. The largest global industrial industrial gas company, “said McNechty. Corresponding to his bullish comments, McCulthy rates Lynn as a buy, and his 20,320 target indicates a reversal of ~ 28% for next year. (To view MN Quality’s track record, click here) Wall Street analysts have a comprehensive explanation on the quality of Linde’s stock, as shown by 15 by reviews overlapping 3 holdings. The stock has a strong buy analyst consensus rating. The stock is priced at .8 250.88, and their રાશ 295.73 average price target indicates an 18% increase in the dollar ahead of them. (See Links Stock Analysis on Tipranx) BlackRock (BLK) Next Up is the world’s largest asset manager. BlackRock has 8. 8.67 trillion in assets under its management. The company It is one of the strongest index funds in the financial scene and had a revenue of Rs.26.200 billion last year, with a net income of Rs.9.49 billion. BlackRock’s latest Q4 report shows its strength as far as numbers go. EPS at 10.02d per share, 12% gradual gain and 20% year-over-year gain. Quarterly revenue of 8 8.8 billion increased 1%. The full-year top line was up 11% from 2019. Even after BlackRock had achieved all this, the Corona crisis had squeezed the economy into 1H20. In the first quarter of this year, BlackRock announced its regular quarterly dividend, and paid-up per share increased 13% to 13 4.13. .5 On an annual payment of 16.52, this yields 2.3%. The company has kept dividends reliable for the last 12 years. Not wanting to miss the lucrative opportunity, Dalio’s fund pulled the trigger on 19,917 shares, giving it a new position in BLK. The value of this new addition? More than 14 million. Brian Bedell, an analyst covering BLK for Deutsche Bank, writes, “We consider the 4Q results to be very good with long-term net income in its products, which, despite the one-time low-fee equity pension fund outflow we expect. Index assets are expected in 1H21 which is in milligrams.The said base fee will have minimal impact on revenue.In addition, the total net flow at 7% growth on annual long-term organic AUM growth Annual organic support management fee growth quarterly record of 13% We expect that the current AUM growth driven by the current flow mix towards fee-rate products will outperform the organic AUM growth. “For this, Bedell BLK rates a bye and indicates its target of 7 837. That stock is 18% ahead of it. (To see Bedell’s track record, click here) Analyst consensus tells a very similar story. BLK has received 6 buy ratings in the last three months against Single Hold – a clear indication that analysts are impressed with the company’s prospects. Shares sell at 710.11 dollars, and an average price of 32 832.17 gives the stock a 17% upside potential. (See BLK Stock Analysis on Tipperenx) ABVV, Inc. (ABBV) ABVV is a big name in the pharma industry. The company is the creator of Hamira, an anti-inflammatory used in the treatment of chronic diseases including rheumatoid arthritis, Crohn’s disease and psoriasis. The company’s other immunosuppressants, Skyrizi and Rinwok, were approved by the FDA in 2019 as treatments for rheumatism and arthritis, respectively, and had combined sales of 2. 2.3 billion last year. Abby expects the drugs to fill a profit gap when Humira patents expire in 2023, with sales reaching 15 15 billion by 2025. Humira is currently the main driver of ABV’s immunology portfolio, and it provides 19 19.8 billion of the portfolio’s આવક 22.2 billion in annual revenue, and a significant portion of the company’s total sales. Throughout the year 2020, in all segments, the ABV reven adjusted to a thin EPS of 10.56. With reven saw revenue of 45.8 billion. In addition to its high-profile anti-inflammatory line, ABVV also has a ‘stable’ of long-established drugs on the market. For example, the company owns Deppac Coat, a common anti-seizure drug. ABBV also maintains an active research pipeline, with many drug candidates studying in the branches of immunology, neuroscience, oncology and virology. Investors have a long-standing commitment to return profits to ABV shareholders. The company has an 8-year reliable – and growing – dividend history. In a recent announcement, the ABV, which was made this month for payments in May, increased its dividend per share by 10% to $ 1.30. At 5.20 per cent per annum, this yields 4..9%. Once again, we are looking for a stock that includes some of Dalio’s advice. Pulling the trigger on ABBV in the fourth quarter, Dalio’s pay firm bought 25,294 shares. At current valuation, this is valued at 66 2.66 million. The Lynch analyst covers off-free Porges ABBV, and is impressed with the company’s advance on the loss of U.S. exclusivity on its best-selling product. “Between the growth path of ABBV’s former Humira portfolio and the expanded portfolio of catalysts in early, mid- and late-stage assets, it is difficult to find a biopharma company in a better position despite their booming LOE. ABBV is poised for 2023, and its growth drivers run in the period before the industry average (top-line) growth (2021-2022) and after 2023 (2024-220-25). Porges gives ABBV an outperform (i.e. buy) rating, and sets a target of $ 140 which indicates 33% room for a one-year side lattice. (To view Porgs’ track record, click here) Overall, there are 10 reviews on ABBV shares, and 9 of them have been purchased – a margin that makes the analyst’s consensus rating strong buy by. The stock is trading at 105.01 and its average price target is 2 122.60. This represents a reversal of 17% over the next 12 months. (See ABBV Stock Analysis on Tiprank) To find good ideas for trading stocks at attractive valuations, visit Tiprank’s Best Stocks to Buy, which unites all of Tiprank’s equity insights. Disclaimer: The opinions expressed in this article are those of specific analysts only. Content is intended for informational purposes only. It is very important to do your own analysis before making any investment.